Navigation Links
Targeted drug therapy prevents exercise-induced arrhythmias
Date:3/29/2009

A 12-year-old Dutch boy bedridden for three years because of an inherited cardiac arrhythmia syndrome can now join his friends on the soccer field thanks to a discovery made by Vanderbilt University Medical Center researchers.

The investigators, led by Bjrn Knollmann, M.D., Ph.D., report this week in Nature Medicine that the clinically available drug flecainide prevents potentially lethal arrhythmias in patients with a specific type of exercise or stress-induced arrhythmia disorder called CPVT.

"It's potentially a breakthrough in the treatment of this rare syndrome," said Knollmann, associate professor of Medicine and Pharmacology.

Patients with CPVT experience abnormally rapid heart rates (tachycardia), usually during exercise or stress, and are at risk for fainting and cardiac arrest. The syndrome kills up to 50 percent of untreated patients, and it may account for some unexplained sudden cardiac deaths in young athletes.

Current treatment has been limited to two medications beta blockers, often used at very high doses, and calcium channel blockers to control the arrhythmias.

Implantable cardioverter defibrillators (ICDs) are placed in patients at high risk for sudden death, but ongoing arrhythmias can result in frequent stressful shocks.

The Dutch patient, for example, experienced ventricular tachycardia and ICD shocks whenever he got out of bed, Knollmann said.

Defibrillator therapy also can be problematic for pediatric patients (CPVT is usually diagnosed in children), who require multiple surgical revisions of their systems.

"For this particular disease, the ICD is a suboptimal treatment," he said. "It's extremely desirable to have a drug treatment that reduces or prevents the ventricular tachycardias, and therefore prevents the ICD shocks."

Knollmann and his team have been studying the molecular defects that trigger arrhythmias. They knew that mutations in two genes that enco
'/>"/>

Contact: Craig Boerner
craig.boerner@vanderbilt.edu
615-322-4747
Vanderbilt University Medical Center
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. St. Jude finds factors that accelerate resistance to targeted therapy in lymphoblastic leukemia
2. Microarray sequence capture speeds large-scale resequencing of targeted genomic regions
3. Researchers combat slowing yields with targeted fertilizer applications
4. Fishing throws targeted species off balance, Scripps study shows
5. New technique allows targeted inactivation of genes in research model
6. Newly identified role for power plants in human cells could lead to targeted therapies
7. Consortium develops new method enabling routine targeted gene modification
8. On the trail of a targeted therapy for blood cancers
9. Cellular discovery may lead to targeted treatment for rare form of anemia
10. Molecular fingerprints point the way to earlier cancer diagnosis and more targeted treatment
11. A new radiation therapy treatment developed for head and neck cancer patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2015)... , April 27, 2015  For more than four ... show has been the premier worldwide event for the ... is a must-attend event for any local, national, or ... the emerging commercial markets and current applications of unmanned ... of this projected $48 billion industry, and how it ...
(Date:4/20/2015)... Huntington Memorial Hospital is the first facility ... miniaturized, wireless monitoring sensor to manage heart failure (HF). ... FDA-approved heart failure monitoring device that has been proven ... to manage heart failure. The CardioMEMS HF ... pulmonary artery (PA) during a non-surgical procedure to directly ...
(Date:4/14/2015)... 14, 2015 NXT-ID, Inc. (NASDAQ: NXTD ... focused on the growing mobile commerce market, announces that ... 2015 New York Design Awards under the category  ,Product ... City Design Awards are part of a global multi-disciplinary ... ratings from the marketplace, industry and judging panel. Winners ...
Breaking Biology News(10 mins):UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 2UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 3UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 4UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 5Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3
... neuroscientists at Georgetown University Medical Center found significant differences ... dyslexia to their non-dyslexic control groups, suggesting that the ... sex., Their study, investigating dyslexia in both males and ... of females with and without dyslexia (in children and ...
... of tissue during surgical operations has the potential to ... to conventional sutures and stapling in intestinal surgery, scientists ... gold-based solder, or sealing material, appears in the journal ... colleagues explain that laser tissue welding (LTW) is a ...
... Sydney, Australia -- Researchers from the University of ... is needed to understand how micro-organisms respond to ... in medical and environmental applications. Although nanosilver ... to silver nano-particles can cause other potentially harmful ...
Cached Biology News:Brain anatomy of dyslexia is not the same in men and women, boys and girls 2Bacteria adapt and evade nanosilver's sting -- new study 2
(Date:5/21/2015)... Patent Offering, The patent’s technology pertains to an ... within a body lumen (open space). Known as ... cost, single-use disposable illumination and camera module (housing). ... and the patent approval was received on January 6, ... the lighting and magnification of the endoscope for different ...
(Date:5/21/2015)... VANCOUVER , May 21, 2015 /PRNewswire/ - ... a clinical stage regenerative medicine company focused on ... an upcoming poster presentation at the International Society ... treatment for chronic Achilles tendinosis currently in a ... on May 29 th from 5:30 PM ...
(Date:5/20/2015)... and Markets ( http://www.researchandmarkets.com/research/x4b7kw/top_technologies ) has announced ... Insights" report to their offering. Technical ... the Health and Wellness sector and has identified top ... in the year 2015. The research service provides an ... wellness technologies that are anticipated to have the highest ...
(Date:5/20/2015)... The global genotyping market is expected to ... period of 2015 to 2020 to reach $17.0billion in ... discovery and development process and to provide personalized therapy, ... this,heavy investments by key manufacturers to offer advanced and ... growth. Browse 113 market data tables & 37 figures ...
Breaking Biology Technology:IpAuctions™ Presents The Worlds Smallest Disposable Illuminated Endoscope For Auction 2IpAuctions™ Presents The Worlds Smallest Disposable Illuminated Endoscope For Auction 3RepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference 2RepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference 3Top Technologies in the Health and Wellness Industry 2015 2Genotyping Market Growing at 22.3% CAGR to 2020: Research Based on Technology, Applications, Opportunities, Challenges and Key Players. 2Genotyping Market Growing at 22.3% CAGR to 2020: Research Based on Technology, Applications, Opportunities, Challenges and Key Players. 3Genotyping Market Growing at 22.3% CAGR to 2020: Research Based on Technology, Applications, Opportunities, Challenges and Key Players. 4Genotyping Market Growing at 22.3% CAGR to 2020: Research Based on Technology, Applications, Opportunities, Challenges and Key Players. 5
... Cardium Therapeutics,(NYSE: CXM ) today reported ... of Medicine showing the long-term outcome of a method ... disorder of the immune system.,The infant children studied had ... arises in infants with a genetic defect that,leaves them ...
... Shares of Common StockAt a Price of $5.00 per ... Group, Inc. (the "Company" or "PharmaNet") (Nasdaq: ... today announced that it has signed a definitive merger ... ("JLL"). Under the terms of the Merger Agreement, JLL ...
... Secondary Endpoints -- CAPACITY 1 Misses Primary Endpoint, Provides ... MAA -BRISBANE, Calif., Feb. 3 InterMune, Inc. (Nasdaq: ... two Phase 3 CAPACITY studies evaluating pirfenidone in patients ... of change in percent predicted Forced Vital Capacity (FVC) ...
Cached Biology Technology:Gene Therapy Field Advances With Important Clinical Findings Reported in the New England Journal of Medicine 2Gene Therapy Field Advances With Important Clinical Findings Reported in the New England Journal of Medicine 3Gene Therapy Field Advances With Important Clinical Findings Reported in the New England Journal of Medicine 4Gene Therapy Field Advances With Important Clinical Findings Reported in the New England Journal of Medicine 5PharmaNet Development Group Agrees to be Acquired by JLL Partners 2PharmaNet Development Group Agrees to be Acquired by JLL Partners 3PharmaNet Development Group Agrees to be Acquired by JLL Partners 4PharmaNet Development Group Agrees to be Acquired by JLL Partners 5PharmaNet Development Group Agrees to be Acquired by JLL Partners 6PharmaNet Development Group Agrees to be Acquired by JLL Partners 7InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF 2InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF 3InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF 4InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF 5InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF 6InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF 7InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF 8InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF 9InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF 10InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF 11
... Hybridization Cassettes facilitate the hybridization of DNA ... standard 25mm x 75mm glass slides. The ... to correct for poor flatness, as is ... its low volume chamber (67uL analytical cavity ...
... reagent is formulated specifically for Alkaline Phosphatase ... levels of activity for both the enzyme ... final dilution. This product has been ... the customer a longer shelf life, resistance ...
... to Lambda Free Light Chain ... chains of human immunoglobulin. ... expressed epitope of lambda chain. Reacts ... free lambda chains but not with ...
... valuable tool for removing SDS detergent from ... in biological samples imparts a negative charge ... enzymatic activity during digestion, and suppresses ion ... mass spectrometry analyses. We recommend that ...
Biology Products: